Skip Ribbon Commands
Skip to main content
Menu

Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1


No Site​ ​Stage of cancer Title of study ​Principal investigator ​Details of trial ​Status
​1​All Solid Tumour​IV

​D3-002
A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours

​Dr Matthew Ng NCT02521844 ​Open
2Epithelial sarcoma, NPC, Gastric, Prostate Ovarian & DLBCLIV​CMAK683X2101
A Phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies		​Dr Daniel Tan NCT02900651​Open
​3Brain​IV​​CBLZ945X2101
A Phase I/II, open-label, multi-center of the safety and efficacy of BZL945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors malignancies.		​Dr Darren Lim NCT02829723​Open
​4​NSCLC, Head and Neck, GIST, CRC, Esophageal IV​​CTNO155X2101
An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors		​Dr Daniel Tan​NCT03114319​Open
​5​​CRC and PDAC​​Advanced​​CTMT212XSG01T
Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma		​Dr David Tai​NCT04303403​Open
​6​​Lung​​LOCALLY ADVANCED/ METASTATIC - First Line​CPDR001C2101
Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients		​Dr Daniel Tan​NCT03064854​Open
​7​​All Solid Tumour​documented RET infusion​LOXO-RET-17001
A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity		​Dr Daniel Tan​NCT03157128​Open
​8​​Non-small cell lung cancer​​IV​​CEGF816X2102
A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC		​Dr Daniel Tan​NCT03333343​On hold
​9​​All Solid Tumour​documented RET infusion​BLU-667-1101
A Phase 1 Study of the Highly-selective RET inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumours		​Dr Daniel Tan​NCT03037385​Open
10NSCLC, Pancreas and all solid tumors ​IV​MCLA-128-CL01
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors		​Dr Justina Lam NCT02912949​Open
11​All Solid Tumour with documented NTRK fusions ​must had prior TRK inhibitor​LOXO-EXT-17005
A Phase 1/2 study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK fusion cancers 		​Dr Daniel Tan NCT03215511Open
12NSCLC, TNBC, PDAC, RCC, Ovarian, CRC, Prostate​IV​CNZV930X2101
A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies		​Dr David Tai NCT03549000​Open
13​​All Solid Tumour​with documented ATM loss​BAY 1895344 / 18594
An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas 		​Dr Daniel Tan NCT03188965​On hold
14​BreastTNBC, not more than 2 prior lines of chemotherapy. Neoadjuvant or adjuvant chemotherapy will count as one prior line.​CADPT01A12101C
A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer		​Dr Tira Tan NCT03742349​​Open
15​NSCLC​Advanced recurrent​BI 1200.275
A dose finding study of continuous and intermittent high-dose (HDI) Afatinib (EGFR Tyrosine Kinase Inhibitor) on CNS metastases and leptomeningeal disease (LMD) in patients with advanced refractory EGFR mutation positive non-small cell lung cancer		​Dr Daniel Tan NCT03711422​Open
16​NSCLC​​with documented EGFR Exon 20 insertion mutation ​CLN-081-001
 A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations		​Dr Daniel Tan​NCT04036682​Open
​17​CRC and PDAC​​with documented KRAS​V941-001
 A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma		​Dr Daniel Tan​NCT03948763​Open
18​Prostate​​Advanced recurrent​Amgen 20180101
 A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer		​Dr Daniel Tan​NCT03792841​Open
​19​​All Solid Tumour​documented RET infusion​LIBRETTO-201
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation		​Dr Daniel Tan​NCT03906331Open
20​NSCLC​​must have prior TKI. Prior adjuvant/neo-adjuvant chemo & IO not allowed​AB928CSP0004
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer		​​Dr Daniel Tan​NCT03846310​​Open
21​All Solid Tumour​​​Advanced recurrent​THOR-707-101
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors		​Dr Tira Tan​NCT04009681​On hold
22​Ovarian​Recurrent​NCC OV-03 (BMS Protocol No. CA209-7WC)
A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients with Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02)		​Dr Jack ChanNCT04620954​Open
23​​​​Melanoma/NSCLC/
esophageal		​IV​NP41300
An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/ Tolerability, Pharmacokinetics and Preliminary Anti Tumor Activity of RO7247669, A PD1-LAG3 Bispecific Antibody, in Patients with Advanced and/or Metastatic Solid Tumors		​Dr Darren Lim​NCT04140500​Open
24​All Solid Tumour​​Advanced recurrent​TAPISTRY
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial 		​Dr Tira Tan​NCT04589845Open
​25​All Solid Tumour​Advanced recurrent​Amgen 20180143
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors		​Dr Daniel Tan​NCT03853109​Open
26​​​All Solid Tumour​Advanced recurrentCJDQ443A12101
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation		​​Dr Daniel TanNCT04699188
​Open

​

Current clinical trials by body parts

No Site​ ​Stage of cancer ​Title of study ​Principal investigator Details of trial Status
1​Bladder​Unresectable or Metastatic Urothelial Cancer​CA209-901
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer		​Dr Ravindran Kanesvaran NCT03036098​Open
2​​BladderNeoadjuvant and adjuvant chemotherpay for non-muscle invasive bladder cancer​CA017-078
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants  with Muscle-Invasive Bladder Cancer 		​Dr Ravindran KanesvaranNCT03661320​Open
3​Breast​premenopausal perimenopausal
HR+
LABC
MBC		​CLEE011A3201C
A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study		Dr Yap Yoon Sim NCT03839823  Open
4​Breast ​Metastatic​BEXMET
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype		​Dr Elaine Lim​NCT04664829​Open
5​​Breast

​Neo adj

HER2 Neg 

ER+

tx naive

high risk

stage II/III

​CA209-7FL
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer		​Dr Yap Yoon Sim NCT0410906​​Open
6​BreastPIK3 CA-Mutant HR+, HER2 - LABC/MBCWO41554
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC 0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant In Patients with Locally Advanced or Metastatic Pik3ca-Mutant Hormone Receptor-Positive, Her2 Negative Breast Cancer 		Dr Yap Yoon Sim NCT04191499       ​Open
7​Breast ​Adjuvant / Metastatic ​TCF20-BRE-01
An open-label, single-institution, dose-determining (Part I) and dose-confirmatory (Part II) study to investigate the optimal dose of Tamoxifen in breast cancer patients harboring different TCF20 rs932376 variant alleles		​Dr Elaine Lim​Pending​Open
8​Breast​HER2 Neg                          ER +  , 1st line                             LABC/MBC​A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER(+), HER2(-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease​Dr Yap Yoon Sim​NCT04478266​Open
​9​Breast​TNBC​WO39391-IMPASSION 030
A Phase III, Multicenter, Randomized, Open-label Study Comparing ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) In Combination With Standard Adjuvant ANTHRACYCLINE/TAXANE-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable TRIPLE-NEGATIVE Breast Cancer 		​Dr Rebecca Dent​NCT03498716​Open
​10​Breast​ER +, HER2-       LABC or MBC​WO42312
A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients with Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer		​Dr Yap Yoon Sim​NCT04576455​Open
11​Colorectal​Neoadjuvant​OTSP-WoOCRC / MK-3475-886
Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer		​Dr Iain Tan NCT03984578​Open
12Colorectal​Adjuvant​ASCOLT
Aspirin For Dukes C And High Risk Dukes B Colon Cancer – An International Multi-Centre, Double Blind, Randomized Placebo Controlled Phase III Trial      		​Dr Tham Chee Kian NCT00565708​Open
13​Endometrial​HER 2 recurrent advanced or mets endometrial carcinoma

​SYD985.003

A phase II study to compare the safety and efficacy of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-expressing recurrent advanced or metastatic endometrial carcinoma who previously progressed on or after first line platinum-based chemotherapy

​Dr Chay Wen Yee​NCT04205630​Open
14​Gynae​Endometrial Ca Newly advanced or recurrent Ca​D9311C00001 (DUO-E)
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer		​Dr Soh Lay Tin​NCT04269200​Open
15​Esophageal​Unresectable Locally Advanced, Unresectable Recurrent,  Metastatic, 1st line​YO42138
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Tiragolumab In Combination With Paclitaxel And Cisplatin Compared With Paclitaxel And Cisplatin As First-Line Treatment In Patients With Unresectable Locally Advanced, Unresectable Recurrent, Or Metastatic Esophageal Squamous Cell Carcinoma		​Dr Matthew Ng​NCT04540211Open
16​Gastric
​Neoadjuvant​INNOVATION
INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer (EORTC-1203-GITCG)		​​​Dr Matthew Ng NCT02205047​Open
17​​Gastric/ Gastroesophageal JunctionMetastatic or locally advancedCP-MGAH22-06
A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer		Dr Matthew Ng NCT04082364​On hold
18​Liver​Adjuvant​WO41535
A Phase III, Multicenter, Randomized, Open-Label Study Of Atezolizumab (Anti-Pd-L1 Antibody) Plus Bevacizumab Versus Active Surveillance As Adjuvant Therapy In Patients With Hepatocellular Carcinoma At High Risk Of Recurrence After Surgical Resection Or Ablation		​Dr Toh Han Chong​NCT04102098​Open
19​Liver​Adv 1st line​EMERALD-1
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma		​Dr David Tai​NCT03778957​Open
20​Liver​Advance/ Metastatic  2nd line​CA224-073
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors		​Dr David Tai​NCT04567615​New
21​​Liver​Neoadjuvant + adjuvant​MK3475-750
OTSP-HCC1 Longitudinal Immune-phenotyping of Surgically Resected HCC following Neoadjuvant and Adjuvant Treatment with MK – 3475		​Dr Toh Han Chong​NCT04224480​Open
22​Lung​LOCALLY ADVANCED/ METASTATIC - First Line ​BO29554
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)		​Dr Daniel Tan NCT03178552​Open
23​Lung​LOCALLY ADVANCED/ METASTATIC - First Line​MK-3475-495
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)		​Dr Daniel Tan NCT03516981​Open
24​Lung​​LOCALLY ADVANCED/ METASTATIC - 2nd Line​MS200095-0031
A Phase II single arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy (INSIGHT2)		​Dr Daniel Tan​NCT03940703​Open
25​Lung​​LOCALLY ADVANCED/ METASTATIC - First Line​TAK-788-3001
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
​Dr Tanujaa ​NCT04129502​Open
26​Lung​​LOCALLY ADVANCED/ METASTATIC - First Line​GO41767
A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide Plus Atezolizumab With or Without Tiragolumab (anti-TIGIT Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
​Dr Darren Lim​NCT04256421​Open
​27​Lung​locally advanced or metastatic, 1st line​ATORG-0003
A Single-arm, Open-label, Phase 2 Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation		​Dr Daniel Tan​NCT04027647​Open
28​Lung​Adjuvant stage II-III ​MeRmaiD-1
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC
​Dr Daniel Tan​NCT04385368​Open
29​Lung​Adjuvant stage II-III ​MERMAID-2
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy
​Dr Daniel Tan​NCT04642469​Open
30​​Lung​LA NSCLC​CA209-73L
A Phase 3, Randomized, Open-Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)		​Dr Daniel Tan​NCT04026412​Open
31​Lung​Mets NSCLC​LIBRETTO-431 - J2G-MC-JZJC
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer		​Dr Daniel Tan​NCT04194944​Open
32​Lung​​Mets NSCLC​HERTHENA-Lung01
A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)		​Dr Darren Lim​NCT04619004​Open
33​​Lymphoma​RELAPSED​MOR208C204 (B-MIND)
 A Phase III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)		​Dr Lim Soon Thye​NCT02763319​Open
34​Nasopharyngeal​​Neoadjuvant / Stage IVA​​NEO-SPACE
Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer		​Dr Darren Lim​NCT03734809​Open
35​Nasopharyngeal

Metastatic or recurrent nasopharyngeal carcinoma

No more than 1 line

​​CA209-796
A phase II trial of Ipililumab in combination with nivolumab in patients with advanced nasopharyngeal carcinoma		​Dr Darren Lim​NCT03097939​Open
36​Nasopharyngeal

​Metastatic or recurrent nasopharyngeal carcinoma

First line

​NRG-HN007
An open-label, phase III study of platinum-gemcitabine with or without nivolumab in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma 		​Dr Darren Lim​NCT04458909​Open
37​Prostate​Metastatic​CA209-7Dx
A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX) 		​Dr Ng Quan Sing​NCT04100018
 
 
 
 
 
 
 
 
 
 
Open
​38​Prostate​Metastatic​XL184-315 (CONTACT-02)
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer 		​Dr Ng Quan Sing​NCT04446117​Open
39​Renal​​Resectable Renal Cancer​​CA209-914
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse		​Dr Ravindran Kanesvaran​NCT03138512​Open
40​​Sarcoma​relapsed/refractory​​E7080-G000-230 (OLIE)
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma		​​Dr Mohamad FaridNCT04154189​Open


General

​No Site​ ​Stage of cancer ​Title of study ​Principal investigator ​Details of trial ​Status
​1​SOLID TUMORS ​LOCALLY ADVANCED / METASTATIC - ANY LINE CLDK378A2X01B
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib 		​Dr Daniel Tan NCT02584933​Open
​2​SOLID TUMORS ​LOCALLY ADVANCED / METASTATIC - ANY LINE​LOXO-TRK-15002 (NAVIGATE)
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors 		​Dr Daniel Tan NCT02576431​Open
​3​SOLID TUMORS ​LOCALLY ADVANCED / METASTATIC - ANY LINE​RXDX-101-02 (STARTRK-2)
An Open-label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements  		​Dr Daniel Tan NCT02568267​Open
4​SOLID TUMORS ​LOCALLY ADVANCED/ METASTATIC – 2nd Line Onwards​CA209-848
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 848)		​Dr Iain Tan NCT03668119​On hold
​5​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards​APL10101 
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors		​Dr Gillianne Lai​NCT03175224​Open
6​SOLID TUMORS ​LOCALLY ADVANCED/ METASTATIC – 2nd Line Onwards​CNIR178X2201
A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma		​Dr Daniel Tan NCT03207867​Open
7​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards​TPX-0005-01
A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)
​Dr Darren Lim​NCT03093116​Open
​8SOLID TUMORS
(currently only HCC and gastric cohorts are opened)

Advanced curatively unresectable solid tumors failing standard therapy.

HCC: must have failed at least 1 line of standard therapy

Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)

Other solid tumours: must have failed at least 1 line of standard therapy

​NCCS-2018-Phase2-PRL3
An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours 		​Dr Matthew Ng​NCT04118114​Open

SingHealth Updates for Healthcare Professionals

HealthXchange E-newsletter Sign-up

Sign up today!

Health Buddy App

Make a Gift

About NCCS

Patient Care

Research & Innovation

Education & Training

Careers

Giving

SingHealth
SingHealth Duke-NUS

​ 11 Hospital Crescent, Singapore 169610  +65 6436 8000


Award1Award2Award3Award4Award5
Singapore Health Awards
© 2021 SingHealth Group. All Rights Reserved.
Best viewed on IE 11, Firefox 27, Chrome 22, and Safari 7 and above.